Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194294 | 0.84 | ALDH1A1 (0.45) | GSK3BL3MBTL1MAPTNPC1RAB9A | |
| SCHEMBL194430 | 0.80 | TSHR (0.49) | GSK3BL3MBTL1MAPTNPC1LMNA | |
| SCHEMBL194501 | 0.80 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27864883 | 0.78 | HDAC3 (0.39) | HDAC3HDAC6GSK3BMAPTRAB9A | |
| SCHEMBL193419 | 0.76 | PTPN1 (0.49) | HDAC1HDAC8MAPTNPC1RAB9A | |
| SCHEMBL8698087 | 0.74 | L3MBTL1 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1156537 | 0.73 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28727176 | 0.73 | KMT2A (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3830886 | 0.73 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31274111 | 0.72 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-11498898-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-15 | — | — | US | disclosed |
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10844011-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3613734-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | TAKEDA PHARMACEUTICALS CO (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3241826-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2765130-B1 | Intermediates for use in a process of producing pyrrole compounds | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-2402313-B1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-08-24 | — | — | EP | disclosed |
| CN-104211618-B | The method preparing azole compounds | 武田药品工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2765130-A2 | Process for producing pyrrole compound | Takeda Pharmaceutical Company Limited (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2402313-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | HDAC3 1911/4885HDAC4 1879/4885HDAC1 4088/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
| US-11498898-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | CYP3A5, CYP3A4, CBR3 | HDAC3 1114/4885HDAC4 1005/4885HDAC1 3092/4885 |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
| US-10844011-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | HDAC3 1938/4885HDAC4 1277/4885HDAC1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.